Dr. Monk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2222 E Highland Ave Ste 400
Phoenix, AZ 85016Phone+1 602-277-4868- Is this information wrong?
Summary
- Dr. Bradley Monk is an obstetrician/gynecologist in Phoenix, AZ and is affiliated with multiple hospitals in the area, including Valleywise Health, St. Joseph's Hospital and Medical Center, Chandler Regional Medical Center, and Mercy Gilbert Medical Center. He received his medical degree from University of Arizona College of Medicine - Tucson and has been in practice 29 years. He specializes in gynecologic oncology and is experienced in general obstetrics and gynecology and gynecologic oncology.
Education & Training
- University of California (Irvine)Residency, Gynecologic Oncology, 1992 - 1995
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Obstetrics and Gynecology, 1988 - 1992
- University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1990 - 1990
- University of Arizona College of MedicineClass of 1988
Certifications & Licensure
- FL State Medical License 2019 - 2026
- AZ State Medical License 2010 - 2025
- CA State Medical License 1990 - 2025
- NV State Medical License 1998 - 2023
- TX State Medical License 1996 - 2018
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2010
- America's Top Doctors for Cancer Castle Connolly, 2008-2009
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
- Join now to see all
Clinical Trials
- Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Start of enrollment: 2002 Apr 01
- Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Start of enrollment: 2003 May 01
- Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(ade...Perhanidis, J., Ghazarian, A., Du, E., Wang, T., Song, J., Golembesky, A., Kalilani, L., Rimel, B., Chase, D., Hurteau, J., Salani, R., Monk, B.> ;Gynecologic Oncology Reports. 2024 Feb 1
- Highlights from the 24th European Congress on Gynaecological Oncology in Istanbul: an ENYGO-IJGC Fellows compilation.Angeles, M., De Vitis, L., Cucinella, G., Bonaldo, G., Bizzarri, N., Agusti, N., Kacperczyk-Bartnik, J., El Hajj, H., Theofanakis, C., Bilir, E., Hsu, H., Estrada, E.,...> ;International Journal of Gynecological Cancer. 2023 Dec 18
- 3 citationsMirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.Giorgio Bogani, Robert L Coleman, Ignace Vergote, Toon van Gorp, Isabelle Ray-Coquard, Ana Oaknin, Ursula Matulonis, David O'Malley, Francesco Raspagliesi, Giovanni Sc...> ;International Journal of Gynecological Cancer. 2024 Apr 1
- Join now to see all
Lectures
- CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer-A phas...2019 ASCO Annual Meeting - 6/1/2019
Other
- The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneumMonk BJ, Birrer MJ
http://www.uptodate.com/contents/the-role-of-angiogenesis-inhibitors-in-epithelial-carcinoma-of-the-
UpToDate, Wolters Kluwer Health - 2013-02-25
Press Mentions
- Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD StatusJune 6th, 2022
- FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) plus Chemotherapy, with or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)October 14th, 2021
- Keytruda Approved as First-Line Advanced Cervical Cancer TherapyOctober 14th, 2021
- Join now to see all
Grant Support
- Strategies Against HPV Related Genital Diseases In WomenNational Cancer Institute2001–2006
Professional Memberships
- Member
- Fellow
- Member
Hospital Affiliations
- Valleywise HealthPhoenix, Arizona
- St. Joseph's Hospital and Medical CenterPhoenix, Arizona
- Chandler Regional Medical CenterChandler, Arizona
- Mercy Gilbert Medical CenterGilbert, Arizona
- Banner - University Medical Center PhoenixPhoenix, Arizona
- HonorHealth John C. Lincoln Medical CenterPhoenix, Arizona
- HonorHealth Scottsdale Shea Medical CenterScottsdale, Arizona
External Links
- Arizona Oncologyhttp://arizonaoncology.com/locations-physicians/physicians/profile-bradley-j-monk-md-facog-facs/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: